(Q51373837)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Karl J Aichberger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Susanne Herndlhofer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Gerit-Holger Schernthaner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Martin Schillinger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Gerlinde Mitterbauer-Hohendanner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Christian Sillaber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

27 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Hematology

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

86

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

533-539

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21538470%20AND%20SRC:MED&resulttype=core&format=json

The biology of chronic myeloid leukemia

30 January 2020

cites work

1 reference

Molecular mechanisms of transformation by the BCR-ABL oncogene

21 January 2018

1 reference

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Optimizing therapy of chronic myeloid leukemia

21 January 2018

1 reference

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.

21 January 2018

1 reference

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

21 January 2018

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

AMN107: tightening the grip of imatinib

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

21 January 2018

1 reference

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

21 January 2018

1 reference

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

21 January 2018

1 reference

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

21 January 2018

1 reference

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment

21 January 2018

1 reference

Imatinib attenuates diabetes-associated atherosclerosis

21 January 2018

1 reference

Large and small vessels atherosclerosis: similarities and differences

21 January 2018

1 reference

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

21 January 2018

1 reference

Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling: potential implications in atherosclerosis and lymphangioleiomyomatosis

21 January 2018

1 reference

Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis

21 January 2018

1 reference

Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1.

21 January 2018

1 reference

Discoidin domain receptor 1 (ddr1) deletion decreases atherosclerosis by accelerating matrix accumulation and reducing inflammation in low-density lipoprotein receptor-deficient mice

21 January 2018

1 reference

Regulation of development, survival and neoplastic growth of mast cells through the c-kit receptor

21 January 2018

1 reference

The riddle of the mast cell: kit(CD117)-ligand as the missing link?

21 January 2018

1 reference

New directions in the treatment of imatinib failure and/or resistance

21 January 2018

1 reference

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference